[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019 Aplastic Anemia R&D Pipeline Drugs, Companies, Trials and Developments

March 2019 | 59 pages | ID: 2263A9BCD1DEN
VPAResearch

US$ 2,199.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global demand for Aplastic Anemia treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Aplastic Anemia are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Aplastic Anemia pipeline companies from advancing their products.
Aplastic Anemia Report Description
The H1-2019 pipeline review report on Aplastic Anemia is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Aplastic Anemia pipeline guide presents information on all active drugs currently being developed for Aplastic Anemia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Aplastic Anemia pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Aplastic Anemia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Aplastic Anemia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Aplastic Anemia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Aplastic Anemia pipeline report includes-
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds
    • For each pipeline product, the following details are provided-
    • Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
    • Current status of development
    • Drug overview
    • Mechanism of Action
    • Pre-clinical and Clinical Trials
REASONS TO BUY
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Aplastic Anemia pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Aplastic Anemia pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Aplastic Anemia pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
GLOBAL APLASTIC ANEMIA PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Aplastic Anemia Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Aplastic Anemia pipeline, H1@2019
Mechanism of Action wise Aplastic Anemia Pipeline Candidates

ACCELERON PHARMA INC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

ADVANCED MEDICAL PROJECTS APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

AMGEN INC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

BIOLINERX LTD APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

CELL SOURCE INC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

CELLENKOS INC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

ELIXIRGEN THERAPEUTICS LLC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

F. HOFFMANN-LA ROCHE LTD APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

GAMIDA CELL LTD APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

HEMOGENYX LLC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

JIANGSU HENGRUI MEDICINE CO LTD APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

REGEN BIOPHARMA INC APLASTIC ANEMIA PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LATEST APLASTIC ANEMIA DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us
Sources and Methodology
Contact Information


More Publications